P. , P. Dreyling, M. Wiestner, and A. , Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era, Blood, vol.117, pp.26-38, 2011.

L. Argatoff, J. Connors, and R. Klasa, Mantle cell lymphoma: a clinicopathologic study of 80 cases, Blood, vol.89, pp.2067-2078, 1997.

P. Jares, D. Colomer, and E. Campo, Molecular pathogenesis of mantle cell lymphoma, Journal of Clinical Investigation, vol.122, issue.10, pp.3416-3423, 2012.
DOI : 10.1172/JCI61272

M. Delfau-larue, W. Klapper, and F. Berger, High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma, Blood, vol.126, issue.5, pp.604-611, 2015.
DOI : 10.1182/blood-2015-02-628792

URL : https://hal.archives-ouvertes.fr/hal-01543670

S. Be-a, R. Vald-es-mas, and A. Navarro, Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proceedings of the National Academy of Sciences, vol.110, issue.4, pp.18250-18255, 2013.
DOI : 10.1073/pnas.1205299110

B. Meissner, R. Kridel, and R. Lim, The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, vol.121, issue.16, pp.3161-3164, 2013.
DOI : 10.1182/blood-2013-01-478834

L. Nygren, S. Baumgartner-wennerholm, and M. Klimkowska, Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma, Blood, vol.119, issue.18, pp.4215-4223, 2012.
DOI : 10.1182/blood-2011-12-400580

V. Fern, O. Salamero, and B. Espinet, Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma, Cancer Res, vol.70, pp.1408-1418, 2010.

A. Queir-os, R. Beekman, and R. Vilarrasa-blasi, Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage, Cancer Cell, vol.30, issue.5, pp.806-821, 2016.
DOI : 10.1016/j.ccell.2016.09.014

D. Chiron, C. Bellanger, and A. Papin, Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma, Blood, vol.128, issue.24, pp.2808-2818, 2016.
DOI : 10.1182/blood-2016-06-720490

N. Saba, D. Liu, and S. Herman, Pathogenic role of B-cell receptor signaling and canonical NF-??B activation in mantle cell lymphoma, Blood, vol.128, issue.1, pp.82-92, 2016.
DOI : 10.1182/blood-2015-11-681460

J. Burger and J. Gribben, The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies, Seminars in Cancer Biology, vol.24, pp.71-81, 2014.
DOI : 10.1016/j.semcancer.2013.08.011

J. Burger and R. Ford, The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies, Seminars in Cancer Biology, vol.21, issue.5, pp.308-312, 2011.
DOI : 10.1016/j.semcancer.2011.09.006

A. Corcione, N. Arduino, and E. Ferretti, CCL19 and CXCL12 Trigger in Vitro Chemotaxis of Human Mantle Cell Lymphoma B Cells, Clinical Cancer Research, vol.10, issue.3, pp.964-971, 2004.
DOI : 10.1158/1078-0432.CCR-1182-3

S. Ek, E. Bj?-orck, and C. H?, Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival, International Journal of Cancer, vol.79, issue.8, pp.2092-2097, 2006.
DOI : 10.1046/j.1365-3083.2003.01217.x

B. Chang, M. Francesco, D. Rooij, and M. , Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients, Blood, vol.122, issue.14, pp.2412-2424, 2013.
DOI : 10.1182/blood-2013-02-482125

X. Zhang, J. Xu, and H. Zhu, T cell counts in peripheral blood in mantle cell lymphoma, Cancer Science, vol.25, issue.10, pp.1471-1476, 2016.
DOI : 10.1007/s10555-006-9001-7

L. Nygren, A. Wasik, and S. Baumgartner-wennerholm, T-Cell Levels Are Prognostic in Mantle Cell Lymphoma, Clinical Cancer Research, vol.20, issue.23, pp.6096-6104, 2014.
DOI : 10.1158/1078-0432.CCR-14-0889

URL : http://clincancerres.aacrjournals.org/content/clincanres/20/23/6096.full.pdf

Z. Yang, A. Novak, and M. Stenson, Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma, Blood, vol.107, issue.9, pp.3639-3646, 2006.
DOI : 10.1182/blood-2005-08-3376

N. Tomita, N. Nakamura, and H. Ikoma, Mantle cell lymphoma is associated with a variable number of PD-1-positive tumor infiltrating T-cells, Blood, vol.128, pp.5317-5317, 2016.

J. Myklebust, J. Irish, and J. Brody, High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells, Blood, vol.121, issue.8, pp.1367-1376, 2013.
DOI : 10.1182/blood-2012-04-421826

URL : http://www.bloodjournal.org/content/bloodjournal/121/8/1367.full.pdf

L. Wang, J. Qian, and Y. Lu, Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells, Haematologica, vol.98, issue.9, pp.1458-1466, 2013.
DOI : 10.3324/haematol.2012.071340

R. Castillo, J. Mascarenhas, and W. Telford, Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4, Leukemia, vol.14, issue.2, pp.292-298, 2000.
DOI : 10.1038/sj.leu.2401664

N. Andersen, J. Larsen, and J. Christiansen, Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures, Blood, vol.96, pp.2219-2225, 2000.

H. Visser, M. Tewis, and R. Willemze, Mantle cell lymphoma proliferates upon IL-10 in the CD40 system, Leukemia, vol.14, issue.8, pp.1483-1489, 2000.
DOI : 10.1038/sj.leu.2401829

D. Chiron, C. Dousset, and C. Brosseau, Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, issue.11, pp.8750-8759, 2015.
DOI : 10.18632/oncotarget.3275

S. Iyengar, L. Ariza-mcnaughton, and A. Clear, Characteristics of human primary mantle cell lymphoma engraftment in NSG mice, British Journal of Haematology, vol.116, issue.1, pp.165-169, 2016.
DOI : 10.1182/blood-2010-01-265769

Y. Koh, S. Shin, and C. Park, Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages, Hematological Oncology, vol.23, issue.9, pp.178-186, 2014.
DOI : 10.1200/JCO.2005.08.133

K. Song, B. Herzog, and M. Sheng, Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma, Cancer Research, vol.73, issue.24, pp.7254-7264, 2013.
DOI : 10.1158/0008-5472.CAN-13-0750

L. Pham, M. Vang, and A. Tamayo, during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease, Leukemia & Lymphoma, vol.96, issue.1, pp.186-193, 2015.
DOI : 10.1016/j.semcancer.2012.02.002

M. Jin, E. Hoster, and M. Dreyling, Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome, Histopathology, vol.114, issue.4, pp.586-592, 2011.
DOI : 10.1182/blood-2009-06-225326

URL : https://hal.archives-ouvertes.fr/hal-00623321

C. Schrader, P. Meusers, and G. Brittinger, Growth pattern and distribution of follicular dendritic cells in mantle cell lymphoma: a clinicopathological study of 96 patients, Virchows Archiv, vol.5, issue.2, pp.151-159, 2006.
DOI : 10.1093/ajcp/110.5.582

Z. Chen, A. Teo, and N. Mccarty, ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy, Clinical Cancer Research, vol.22, issue.1, pp.187-199, 2016.
DOI : 10.1158/1078-0432.CCR-15-0987

D. Medina, L. Goodell, and J. Glod, Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor ??B pathways, Haematologica, vol.97, issue.8, pp.1255-1263, 2012.
DOI : 10.3324/haematol.2011.040659

A. Kurtova, A. Tamayo, and R. Ford, Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting, Blood, vol.113, issue.19, pp.4604-4613, 2009.
DOI : 10.1182/blood-2008-10-185827

C. Do~-nate, V. Kumar, A. Imhof, and B. , Anti-JAM-C therapy eliminates tumor engraftment in a xenograft model of mantle cell lymphoma, Journal of Leukocyte Biology, vol.100, issue.5, pp.843-853, 2016.
DOI : 10.1189/jlb.1HI1114-549RR

D. Chiron, D. Liberto, M. Martin, and P. , Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma, Cancer Discovery, vol.4, issue.9, pp.1022-1035, 2014.
DOI : 10.1158/2159-8290.CD-14-0098

A. Hadzidimitriou, A. Agathangelidis, and N. Darzentas, Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases, Blood, vol.118, issue.11, pp.3088-3095, 2011.
DOI : 10.1182/blood-2011-03-343434

A. Navarro, G. Clot, and C. Royo, Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features, Cancer Research, vol.72, issue.20, pp.5307-5316, 2012.
DOI : 10.1158/0008-5472.CAN-12-1615

R. Young and L. Staudt, Targeting pathological B cell receptor signalling in lymphoid malignancies, Nature Reviews Drug Discovery, vol.12, issue.3, pp.229-243, 2013.
DOI : 10.1016/j.ccr.2007.08.011

J. Myklebust, J. Brody, and H. Kohrt, Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling, Blood, vol.129, issue.6, pp.759-770, 2017.
DOI : 10.1182/blood-2016-05-718494

URL : https://hal.archives-ouvertes.fr/hal-01475956

S. Koehrer and J. Burger, B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies, Clin Adv Hematol Oncol, vol.14, pp.55-65, 2016.

B. Hock, J. Mckenzie, and N. Patton, Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies, Cancer, vol.101, issue.10, pp.2148-2157, 2006.
DOI : 10.4049/jimmunol.172.4.2011

M. Sonbol, M. Maurer, and M. Stenson, Elevated soluble IL-2R??, IL-8, and MIP-1?? levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma, American Journal of Hematology, vol.117, issue.12, pp.223-227, 2014.
DOI : 10.1182/blood-2010-05-283820

L. Zhang, J. Yang, and J. Qian, Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells, Blood, vol.120, issue.18, pp.3783-3792, 2012.
DOI : 10.1182/blood-2012-04-424630

C. Zhang, H. Xin, and W. Zhang, CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer, Immunity, vol.44, issue.4, pp.913-923, 2016.
DOI : 10.1016/j.immuni.2016.04.003

S. Bernard, D. Danglade, and L. Gardano, Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma, International Journal of Cancer, vol.105, issue.12
DOI : 10.1182/blood-2004-10-4054

G. Epron, P. Ame-thomas, L. Priol, and J. , Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling, Leukemia, vol.91, issue.1, pp.139-148, 2012.
DOI : 10.1016/j.cell.2010.07.044

URL : https://hal.archives-ouvertes.fr/inserm-00869028

D. Dorfman and G. Pinkus, Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23, Mod Pathol, vol.7, pp.326-331, 1994.

F. Baran-marszak, M. Boukhiar, and S. Harel, Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma, Haematologica, vol.95, issue.11, pp.1865-1872, 2010.
DOI : 10.3324/haematol.2009.019745

H. Zhang and N. Mccarty, Tampering with cancer chemoresistance by targeting the TGM2-IL6-autophagy regulatory network, Autophagy, vol.13, issue.3, pp.627-628, 2017.
DOI : 10.1080/15548627.2016.1271516

Y. Kim and K. Eom, Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells, Immune Network, vol.14, issue.6, pp.296-306, 2014.
DOI : 10.4110/in.2014.14.6.296

R. Rahal, M. Frick, and R. Romero, Pharmacological and genomic profiling identifies NF-??B???targeted treatment strategies for mantle cell lymphoma, Nature Medicine, vol.1, issue.1, pp.87-92, 2014.
DOI : 10.1093/bib/bbs017

L. Fu, Y. Lin-lee, and L. Pham, Constitutive NF-??B and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas, Blood, vol.107, issue.11, pp.4540-4548, 2006.
DOI : 10.1182/blood-2005-10-4042

L. Pham, A. Tamayo, and L. Yoshimura, Inhibition of Constitutive NF-??B Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis, The Journal of Immunology, vol.171, issue.1, pp.88-95, 2003.
DOI : 10.4049/jimmunol.171.1.88

W. Hofmann, S. De-vos, and K. Tsukasaki, Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray, Blood, vol.98, issue.3, pp.787-794, 2001.
DOI : 10.1182/blood.V98.3.787

URL : http://www.bloodjournal.org/content/bloodjournal/98/3/787.full.pdf

S. Katz, J. Labelle, and H. Meng, Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells, Blood, vol.123, issue.6, pp.884-893, 2014.
DOI : 10.1182/blood-2013-04-499079

URL : http://www.bloodjournal.org/content/bloodjournal/123/6/884.full.pdf

T. Lwin, J. Lin, and Y. Choi, Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a, Blood, vol.116, issue.24, pp.5228-5236, 2010.
DOI : 10.1182/blood-2010-03-275925

H. Kluin-nelemans, E. Hoster, and O. Hermine, Treatment of Older Patients with Mantle-Cell Lymphoma, New England Journal of Medicine, vol.367, issue.6, pp.520-531, 2012.
DOI : 10.1056/NEJMoa1200920

L. Gouill and S. , Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group, p.2016, 2017.

O. Hermine, E. Hoster, and J. Walewski, Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network, The Lancet, vol.388, issue.10044, pp.565-575, 2016.
DOI : 10.1016/S0140-6736(16)00739-X

A. Goy, R. Sinha, and M. Williams, Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study, Journal of Clinical Oncology, vol.31, issue.29, pp.3688-3695, 2013.
DOI : 10.1200/JCO.2013.49.2835

M. Wang, L. Fayad, and N. Wagner-bartak, Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial, The Lancet Oncology, vol.13, issue.7, pp.716-723, 2012.
DOI : 10.1016/S1470-2045(12)70200-0

F. Zaja, D. Luca, S. Vitolo, and U. , Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers, Haematologica, vol.97, issue.3, pp.416-422, 2012.
DOI : 10.3324/haematol.2011.051813

J. Gribben, N. Fowler, and F. Morschhauser, Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma, Journal of Clinical Oncology, vol.33, issue.25, pp.2803-2811, 2015.
DOI : 10.1200/JCO.2014.59.5363

J. Westin, F. Chu, and M. Zhang, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, The Lancet Oncology, vol.15, issue.1, pp.69-77, 2014.
DOI : 10.1016/S1470-2045(13)70551-5

A. Goy, S. Bernstein, and B. Kahl, Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study, Annals of Oncology, vol.20, issue.3, pp.520-525, 2009.
DOI : 10.1093/annonc/mdn656

W. Lamm, H. Kaufmann, and M. Raderer, Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma, Haematologica, vol.96, issue.7, pp.1008-1014, 2011.
DOI : 10.3324/haematol.2011.041392

URL : http://www.haematologica.org/content/haematol/96/7/1008.full.pdf

M. Wang, S. Rule, and P. Martin, Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma, New England Journal of Medicine, vol.369, issue.6, pp.507-516, 2013.
DOI : 10.1056/NEJMoa1306220

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513941/pdf

M. Furtado, M. Wang, and B. Munneke, Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma, British Journal of Haematology, vol.369, issue.1, pp.131-134, 2015.
DOI : 10.1056/NEJMoa1306220

URL : http://onlinelibrary.wiley.com/doi/10.1111/bjh.13275/pdf

H. Kohrt, I. Sagiv-barfi, and S. Rafiq, Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity, Blood, vol.123, issue.12, pp.1957-1960, 2014.
DOI : 10.1182/blood-2014-01-547869

URL : http://www.bloodjournal.org/content/bloodjournal/123/12/1957.full.pdf

R. Maffei, S. Fiorcari, and S. Martinelli, Targeting neoplastic B cells and harnessing microenvironment: the ???double face??? of ibrutinib and idelalisib, Journal of Hematology & Oncology, vol.88, issue.6, p.60, 2015.
DOI : 10.1002/ajh.23433

M. Davids, A. Roberts, and J. Seymour, Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Journal of Clinical Oncology, vol.35, issue.8, pp.826-833, 2017.
DOI : 10.1200/JCO.2016.70.4320